 | Up a level |
Cummings, J; Zweifel, M; Smith, N; Ross, P; Peters, J; Rustin, G; Price, P; Middleton, M R; Ward, T; Dive, C (2012). Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial. British journal of cancer, 106(11), pp. 1766-71. Basingstoke: Nature Publishing Group 10.1038/bjc.2012.165
Zweifel, M; Matozan, K; Dahinden, C; Schaffner, T; Mohacsi, P (2010). Eotaxin/CCL11 levels correlate with myocardial fibrosis and mast cell density in native and transplanted rat hearts. Transplantation proceedings, 42(7), pp. 2763-6. New York, N.Y.: Elsevier 10.1016/j.transproceed.2010.05.152
Leyvraz, S; Zweifel, M; Jundt, G; Lissoni, A; Cerny, T; Sessa, C; Fey, M; Dietrich, D; Honegger, HP; Swiss, Group for Clinical Cancer Research (2006). Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Annals of oncology, 17(4), pp. 646-51. Oxford: Oxford University Press 10.1093/annonc/mdl020
